Project Grant R44GM128472

Award Date 1/1/19
Completion Date 8/31/23
Dollars Obligated $4.2M
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
San Carlos, CA 94070, USA
Similar Awards
This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000 to Cellecho, Inc., a minority-owned small business, to develop a microchip-based technology for advanced cell engineering. The project aims to create a platform that leverages acoustic-electric micro-vortices to precisely and efficiently deliver genetic materials like DNA, mRNA, and proteins to cells, enabling complex cell...
The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $658,336 to Rarecyte, Inc. to develop the ORION2 instrument, a system that will enable highly multiplexed spatial profiling of tumor and tissue samples. The key products and services to be delivered under this 3-year award (June 2025 - May 2028) include: Developing an automated imaging system with adaptive controls to balance speed of data acquisition and image...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides $306,860 to Mixedlcmedia LLC, a small disadvantaged business, to develop and evaluate a prototype ultra-low flow liquid chromatography platform based on their proprietary porous layer open-tubular (PLOT) and monolithic nanocolumn technologies. The goal is to create a commercialization-ready LC system that enables deep proteomic...
This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, provides $349,171 to Cellchorus Inc. to develop an integrated computer vision system called LF-TIMING (Label-Free TIMING). The goal is to enable large-scale, label-free profiling of cell-cell interactions, particularly between immune cells and tumor cells. The LF-TIMING system will leverage deep neural networks to accurately analyze phase-contrast video recordings,...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $295,561 to Biosensing Instrument Inc. to develop a commercial prototype of their Plasmonic Scattering Microscopy (PSM) technology. The PSM system aims to enable high-throughput, label-free quantification of membrane protein binding kinetics on single cells in their native cellular microenvironment. This represents a...
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...

PLATFORM FOR GENOTYPING AND PHENOTYPING EACH CELL IN A HIGH THROUGHPUT ASSAY - ABSTRACT ONE OF THE RECURRING QUESTIONS THAT CONTINUES TO PIQUE THE INTEREST OF ACADEMICS AND CLINICIANS IS TO UNDERSTAND THE FUNCTIONAL, TRANSCRIPTIONAL, AND EPIGENETIC PROGRAMS OF RARE CELLS OFTEN IMPLICATED IN TUMOR RECURRENCE, NEUROLOGICAL DISORDERS, CHRONIC INFECTIONS, AND OTHER DISEASES. MASSIVELY PARALLEL SINGLE CELL GENOMIC TOOLS CAN PARTIALLY ADDRESS THIS MARKET NEED; HOWEVER, THE SCIENTIFIC COMMUNITY HAS MADE IT CLEAR THAT DIGITAL TRANSCRIPT COUNTING IS INSUFFICIENT, AND THERE IS STRONG PULL FOR INSTRUMENTS THAT PROVIDE MORE COMPREHENSIVE, MULTI- DIMENSIONAL SINGLE CELL DATASETS. IN PARTICULAR, THERE IS A NEED FOR HIGH-THROUGHPUT SINGLE CELL PHENOTYPING TOOLS, WHICH HAS LAGGED BEHIND GENOMICS TOOL DEVELOPMENT DUE TO THE INCREASED DIFFICULTY OF WORKING WITH LIVE CELLS. TO MEET THIS DEMAND, CELLDOM IS DEVELOPING A PLATFORM THAT COMBINES IMAGE-BASED PHENOTYPING WITH SINGLE CELL TRANSCRIPTOMICS AT THE MASSIVE SCALES NECESSARY TO MEASURE BOTH LIVE CELL FUNCTION AND GENE EXPRESSION AT THE DESIRED ENDPOINT. WE ACHIEVE THIS CONVERGENCE BY UTILIZING EFFICIENT MICROFLUIDIC TRAP ARRAYS PATTERNED WITH LOCALLY PRINTED DNA BARCODES, WHICH ALLOWS US TO BOTH TAKE IMAGES OF SINGLE CELLS AND PREPARE BARCODED SCRNA-SEQ LIBRARIES OF THE SAME CELLS. BUILDING ON THE SOLID PROGRESS IN OUR PHASE I AWARD, IN WHICH WE DEMONSTRATED THAT THE STEPS IN OUR WORKFLOW ARE ALL TECHNICALLY FEASIBLE AND COMPATIBLE, WHICH INCLUDE THE ABILITY TO PRINT DNA BARCODES INSIDE SEALED MICROFLUIDIC CHIPS, TRAP SINGLE CELLS IN AN ARRAY, ACQUIRE HIGH-RESOLUTION IMAGES OF EACH CELL, AND FINALLY PREPARE CDNA LIBRARIES FROM BARCODED PRIMERS ATTACHED TO SURFACES, IN THIS PHASE II, WE WILL UNIFY THIS WORKFLOW AND DEMONSTRATE THE ULTIMATE GOAL OF DEPLOYING OUR APPROACH IN A DRUG DISCOVERY PLATFORM THAT COMBINES TIME LAPSE IMAGING AND HIGH-RESOLUTION TRANSCRIPTOME ANALYSIS OF SINGLE CELLS. OUR WORK PLAN IS SUMMARIZED IN THREE SPECIFIC AIMS. OUR FIRST AIM IS TO SHOW THAT THOUSANDS OF UNIQUELY BARCODED PCR PRIMERS CAN BE PRINTED INSIDE OUR CHIPS IN ONE UNIQUE PRIMER PER CHAMBER FORMAT, AND THAT THESE CHIPS CAN BE USED IN THE PREPARATION OF HIGH QUALITY SCRNA-SEQ LIBRARIES WITH LOW CHAMBER CROSS-CONTAMINATION. OUR SECOND AIM IS TO DEMONSTRATE THAT THIS TRANSCRIPTOMICS WORKFLOW CAN BE SUCCESSFULLY IMPLEMENTED AFTER EXTENDED DURATION IN VITRO CELL CULTURE, DURING WHICH TIME THE BARCODES ARE CONTINUALLY EXPOSED TO ENZYMES PRESENT IN THE SERUM AND ANY EXTRACELLULAR SECRETIONS. OUR THIRD AIM IS TO SHOW THAT KNOWLEDGE OF THE SPECIFIC BARCODES ALLOWS THE TRANSCRIPTS DERIVED FROM SPECIFIC CHAMBERS TO BE SELECTIVELY ENRICHED DURING THE POOLED AMPLIFICATION STEPS - THIS WILL BE USED TO DEMONSTRATE TARGETED SEQUENCING OF HIGH-PRIORITY CLONES, WHICH IS OF PARTICULAR INTEREST TO OUR TARGET CUSTOMERS. AFTER ALL THREE AIMS HAVE BEEN INDIVIDUALLY DEMONSTRATED, THEY WILL BE COMBINED IN A FINAL DEMONSTRATION SHOWING THE ABILITY TO IDENTIFY DRUG-RESISTANT CLONES AND PROBE THEIR TRANSCRIPTOMIC SIGNATURES AT HIGH RESOLUTION. WE EXPECT THIS DEMONSTRATION WILL EXCITE POTENTIAL CUSTOMERS AND ENTICE THEM TO PURCHASE CELLDOM INSTRUMENTS FOR DRUG DEVELOPMENT APPLICATIONS, THERAPEUTICS, AND CLINICAL DIAGNOSTICS.

Posted 9/21/21, 12:00 AM